Showing 2671-2680 of 4881 results for "".
DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibilityYour Destination for the Latest Developments in #Dermatology in Print and Online
https://practicaldermatology.com/topics/practice-management/your-destination-for-the-latest-developments-in-dermatology-in-print-and-online/21135/Laser Tattoo Removal and the Use of Stacked Treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-tattoo-removal-and-the-use-of-stacked-treatments/19309/Tattoo removal procedures have been offered since the late 1990's, but are more effective than ever. This improvement is due to the implementation of stack treatments, during which four sessions can be performed at one time. To show the advances in this procedure, Dr. Joel Schlessinger walks you thrComorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.Patient-Centered Wound Healing
https://practicaldermatology.com/topics/feature/patient-centered-wound-healing/26645/Patient-Centered Wound HealingA Tale of Two Toxins
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-tale-of-two-toxins/22074/From a recent approval to a late-stage candidate, the field is evolving. Experts weigh in on the latest.Robert Grant Steps Down at Alphaeon; Skin Cancer Special Edition
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-robert-grant-steps-down-at-alphaeon-skin-cancer-special-edition/18595/Robert Grant is no longer CEO of lifestyle healthcare company Alphaeon. Mr. Grant founded Alphaeon in 2013 as a wholly owned subsidiary of Strathspey Crown LLC, a private equity firm located in Newport Beach, CA, where he serves as Chairman. Also in this issue, a closer look at skin cancer. May is SDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sTaking a More Holistic View of the Pathogenesis of Acne
https://practicaldermatology.com/topics/acne-rosacea/taking-more-holistic-view-pathogenesis-acne/26539/Taking a More Holistic View of the Pathogenesis of Acne